Aperture Investors, LLC Finch Therapeutics Group, Inc. Transaction History

Aperture Investors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.75 - $2.88 $26,136 - $43,012	-14,935 Reduced 7.19%	192,794 $322,000
Q2 2022 Aug 15, 2022	BUY	$1.91 - $5.11 $23,875 - $63,875	12,500 Added 6.4%	207,729 $590,000
Q4 2021 Feb 14, 2022	SELL	$8.95 - $16.88 $329,019 - $620,542	-36,762 Reduced 15.85%	195,229 $1.95 Million
Q3 2021 Nov 15, 2021	SELL	$12.2 - $16.75 $1.06 Million - $1.46 Million	-87,131 Reduced 27.3%	231,991 $3.02 Million
Q2 2021 Aug 16, 2021	SELL	$12.03 - $17.51 $1.81 Million - $2.63 Million	-150,462 Reduced 32.04%	319,122 $4.49 Million

Q1 2021 May 17, 2021	BUY	$15.54 - $21.32 $7.3 Million - $10 Million	469,584 New	469,584 $7.47 Million

Ticker FNCH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,688,400
Market Cap $63.4M
Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...

Get notified when there are updates to the investment portfolio of Aperture Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Aperture Investors, LLC with notifications on news.